不同抗菌药物治疗肝硬化上消化道出血感染患者的有效性和安全性评价探究

Evaluation of the Effectiveness and Safety of Different Antibacterial Drugs in the Treatment of Patients with Liver Cirrhosis and Upper Gastrointestinal Bleeding Infection

目的探究肝硬化上消化道出血感染患者采用不同抗菌药物治疗的效果。方法选择2019年6月—2020年6月该院120例肝硬化上消化道出血感染患者为研究对象,根据治疗方法不同分成Ⅰ组、Ⅱ组和Ⅲ组,每组40例,分别予头孢哌酮舒巴坦、头孢曲松钠与亚胺培南西司他丁钠静脉滴注治疗。比较3组细菌清除率、治疗效果、不良反应发生率和生活质量量表(SF-36)评分。结果Ⅱ组、Ⅲ组细菌清除率74.29%、75.00%低于Ⅰ组94.59%,差异有统计学意义(χ^(2)=5.731,P<0.05;χ^(2)=5.474,P<0.05);Ⅱ组细菌清除率74.29%低于Ⅲ组75.00%,差异无统计学意义(χ^(2)=0.045,P>0.05);Ⅱ组、Ⅲ组总有效率80.00%、77.50%低于Ⅰ组95.00%,差异有统计学意义(χ^(2)=4.114,P<0.05;χ^(2)=5.165,P<0.05);Ⅱ组总有效率80.00%高于Ⅲ组77.50%,差异无统计学意义(χ^(2)=0.075,P>0.05);Ⅰ组不良反应总发生率2.50%低于Ⅱ组20.00%与Ⅲ组20.00%,差异有统计学意义(χ^(2)=4.507,P<0.05;χ^(2)=4.507,P<0.05);Ⅱ组、Ⅲ组不良反应总发生率20.00%、20.00%比较,差异无统计学意义(χ^(2)=0.000,P>0.05);Ⅰ组SF-36总体评分(87.21±4.56)分高于Ⅱ组(78.28±4.06)分、Ⅲ组(78.10±4.12)分,差异有统计学意义(t=9.250,P<0.05;t=9.375,P<0.05)。结论肝硬化上消化道出血感染采用头孢哌酮舒巴坦治疗的临床效果及安全性高于亚胺培南西司他丁钠、头孢曲松钠。

Objective To explore the effect of different antibacterial drugs on patients with upper gastrointestinal bleeding infection in liver cirrhosis.Methods From June 2019 to June 2020,120 patients with liver cirrhosis and upper gastrointestinal bleeding infection in the hospital were selected as the research objects.According to different treatment methods,they were divided into groupsⅠ,ⅡandⅢ,with 40 cases in each group,and received cephalosporin.Piperone and sulbactam,ceftriaxone sodium and imipenem and cilastatin sodium were injected intravenously.Compared the three groups of bacteria clearance rate,treatment effect,incidence of adverse reactions and quality of life scale(SF-36)score.Results The bacterial clearance rate of group II and group III was 74.29%and 75.00%lower than that of group I 94.59%,the difference was statistically significant(χ^(2)=5.731,P<0.05;χ^(2)=5.474,P<0.05);the bacterial clearance rate of group II was 74.29%lower than 75.00%of groupⅢ,the difference was not statistically significant(χ^(2)=0.045,P>0.05);the total effective rate of groupⅡandⅢwas 80.00%,77.50%was lower than 95.00%of groupⅠ,the difference was statistically significant(χ^(2)=4.114,P<0.05;χ^(2)=5.165,P<0.05);the total effective rate of groupⅡwas 80.00%higher than that of groupⅢ77.50%,the difference was not statistically significant(χ^(2)=0.075,P>0.05);the total number of adverse reactions in groupⅠ2.50%was lower than 20.00%of groupⅡand 20.00%of groupⅢ,the difference was statistically significant(χ^(2)=4.507,P<0.05;χ^(2)=4.507,P<0.05);the total incidence of adverse reactions in groupsⅡandⅢwas 20.00%and 20.00%,the difference was not statistically significant(χ^(2)=0.000,P>0.05);the overall score of SF-36 in group I(87.21±4.56)points was higher than that in group II(78.28±4.06)points,and group III(78.10±4.12)points,the difference was statistically significant(t=9.250,P<0.05;t=9.375,P<0.05).Conclusion The clinical effect and safety of cefoperazone and sulbactam in the treatment of upper gastrointestinal bleeding infection in liver cirrhosis are higher than that of imipenem and cilastatin sodium and ceftriaxone sodium.It is worthy of promotion.